Positioning no disclosures inside 60 days, left as found
Options put/call open interest 16.21, read 2026-11-02
Ethical does not pass the values gate
Price14.62 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markdown21.39-31.7% to today ✓Accumulation gives way to Markdown after an 11% slide in 9 days
2026-10-02Read Accumulation24.03-39.2% to today Distribution gives way to Accumulation after a 42% rise in 2 weeks
2026-09-15Read Distribution16.93-13.6% to today ✓Accumulation gives way to Distribution after a 31% slide in 11 weeks
2026-07-02Read Accumulation24.43-40.2% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Unusual Machines, Inc. holds its Markdown at $14.62. The statistical read favours the sellers, held for 49 days.
As held on the ledger · 2026-11-03
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 49 days
Price at the screen
$14.62
Valuation
N/A trailing · -75.55 forward price to earnings
Values screen
FAIL· score 70.0
Beta
14.74
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.44%
Below 33%
Interest-bearing debt is just 1.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
21.46%
Below 33%
Cash held in interest-bearing accounts and securities is 21.5% of assets, under the one-third limit.
Pass
Receivables
57.37%
Below 49%
Money owed to the company is 57.4% of assets, above the 49% limit.
Fail
Revenue purity
16.35%
Below 5%
16.3% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Unusual Machines,'s business is fine, but its receivables are about 57% of its assets, just over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when UMAC's ethical verdict changes
Today UMAC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.80x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UMAC trades on NYSE American. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markdown$15.53+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$15.53+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$15.53-6.6%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown$16.62+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markdown$16.62+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$16.62-6.3%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$17.73+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25.
2026-10-18Markdown$17.73-17.1%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 17.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 122% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25.
2026-10-11Markdown · changed$21.39-11.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 122% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 41.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 122% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 155%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (6 analysts) rates it strong buy, with a mean price target of $25.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
